On February 19, 2020 Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, reported that it will report its fourth quarter and full year 2019 financial results on Tuesday, February 25, 2020 (Press release, Iovance Biotherapeutics, FEB 19, 2020, View Source [SID1234554512]). Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. EST.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To participate in the conference call, please dial 1-844-646-4465 (domestic) or 1-615-247-0257 (international) and reference the access code 4693108. The live webcast can be accessed in the Investors section of the Company’s website at www.iovance.com. The archived webcast will also be available for one year in the Investors section at www.iovance.com.

On February 19, 2020 Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) reported that it will host a live webcast on Wednesday, February 26th at 11:30 a.m. Eastern Time to discuss its 2019 financial results and report on pipeline and business progress (Press release, Ionis Pharmaceuticals, FEB 19, 2020, View Source [SID1234554529]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Click here to access the audio webcast and slides. A webcast replay will remain posted on Ionis’ website for a limited time.

On February 18, 2020 Horizon Therapeutics plc (Nasdaq: HZNP) reported that the Company will participate in the following conference in March (Press release, Horizon Therapeutics, FEB 18, 2020, https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-present-cowen-and-company-40th-annual [SID1234554443]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cowen and Company 40th Annual Health Care Conference

Date: Tuesday, Mar. 3, 2020
Presentation Time: 12 p.m. ET
Location: Boston
The conference presentation will be webcast live and may be accessed by visiting Horizon’s website at View Source A replay of the webcast will be available for the event.

On February 18, 2020 Guided Therapeutics, Inc. (Pink Sheets: GTHP), the maker of a rapid and painless cervical cancer detection test based on its patented biophotonic technology, reported it had achieved significant progress with the U.S. FDA in restarting its efforts for sales and marketing approval of its LuViva Advanced Cervical Scan (Press release, Guided Therapeutics, FEB 18, 2020, View Source [SID1234554459]). After a succession of conference calls, emails and letters exchanged with FDA over the past 30 days, the Company was encouraged by the agency to file a Pre-submission document detailing its approach for a new clinical trial to support U.S. approval. The Company filed Pre-Submission document with FDA on February 17, 2020. The Pre-submission document is designed to elicit comment from FDA regarding the clinical trial so that a study protocol can be completed and the clinical trial started.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We have been pleased by FDA’s rapid responses to our plan for moving ahead with the approval process, which has allowed us to complete the initial phases of the study design ahead of schedule," said Gene Cartwright, CEO. "If our plan is accepted by FDA, we expect to complete and file the study protocol for comment within about 30 to 60 days, depending on how rapidly FDA responds to our recently filed Pre-submission document."

On February 18, 2020 Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, reported that its President and Chief Executive Officer, Peter L. Hoang, will present at two upcoming investor conferences (Press release, Marker Therapeutics, FEB 18, 2020, View Source [SID1234554475]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Details

Cowen 40th Annual Health Care Conference
Date: Wednesday, March 4, 2020
Time: 8:40 a.m. ET
Location: Boston, MA

Oppenheimer 30th Annual Healthcare Conference
Date: Wednesday, March 18, 2020
Time: 1:35 p.m. ET
Location: New York, NY

Live webcasts of the presentations will be accessible from the investors section of the company’s website at markertherapeutics.com and will be available for replay following the event.